hema.to news

hema.to has closed a €3.6 million financing round led by LUMO Labs, an impact-driven Dutch venture capital firm. This financing will help hema.to pursue product-market fit for its clinical-grade AI software for blood cancer and other cytometry-based blood tests.

hema.to’s committed investors include Elaia and Clément Vanden Driessche, Heal Capital and Christian Lautner, HTGF | High-Tech Gründerfonds and Dr. Nik Raupp, Labor Becker MVZ eGbR, Marc Becker, Malte von Trotha, and angel investor Thomas Henkel.

New investors include Bayern Kapital and Matthias Buchinger, Cross Atlantic Angels with Jens Weitzel and Niklas Herriger, and Akwa Group with Pim Hollestelle and Thomas Hannes.

The round strengthens hema.to’s work to build innovative cytometry technology that supports earlier diagnoses and better treatment decisions.

hema.to’s AI model combines supervised and clustering approaches to detect small pathological B-cell populations in blood and bone marrow samples. Key features include:

• Efficient identification of populations as small as 3% of total cells
• Differentiation of six B-cell neoplasms: CLL, MCL, HCL, FL, MZL, and DLBCL
• Detection of previously unnoticed secondary B-NHL clones
• Optimization for a low false-negative rate, enabling fast, automated screening

The model offers systematic, rapid analysis to aid clinical B-cell neoplasm flow cytometry. View the full poster.

In May, hema.to closed its seed round with Elaia Partners, Heal Capital, and HTGF to bring precision diagnostics to immune medicine.

Elaia Managing Partner Anne-Sophie Carrese said that the founding team’s entrepreneurial and research experience, together with hema.to’s plans to scale its go-to-market strategy, fit Elaia’s deep-tech seed investment thesis.

Read the press release on tech.eu.

hema.to achieved FDA compliance as a Class I device less than four months after receiving its CE mark. This was made possible by hema.to’s team and regulatory partners, including QServe Group, Jennifer Hadfield, and Be-on-Quality.

The photo shows Aleks and Jennifer registering the device; the FDA sent the good news the following day.

hema.to was clinically validated in an international, four-center clinical study. Blood cancer diagnoses were made twice as fast and at clinical grade with support from hema.to’s decision-support software.

Download the press release.

hema.to won first prize at the Medical Innovation Night in Nürnberg. The jury included Medical Valley EMN e. V., Siemens Healthineers, aescuvest, GWQ ServicePlus AG, IONOS, and Fraunhofer IIS.

The €20,000 prize supports hema.to’s exploration of partnerships with GWQ and Siemens Healthineers.

hema.to achieved compliance with the IVDD. The company conforms to ISO 13485 for quality management, ISO 14971 for risk management, ISO 62366 for usability, ISO 62304 for software life-cycle management, and IEC 82304 for health software.